HC Wainwright Issues Pessimistic Outlook for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($1.10) per share for the year, down from their prior estimate of ($1.06). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.21) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.04) EPS.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Piper Sandler boosted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Up 9.8 %

Shares of NASDAQ KPTI opened at $0.70 on Friday. The firm’s 50-day moving average is $0.75 and its two-hundred day moving average is $0.81. Karyopharm Therapeutics has a 12-month low of $0.58 and a 12-month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period last year, the firm earned ($0.30) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KPTI. Point72 DIFC Ltd acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth $31,000. Geode Capital Management LLC boosted its stake in Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after buying an additional 43,856 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the period. FMR LLC increased its stake in shares of Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $143,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).